Key facts
- Drug Hunter (Media and Information Services (B2B))’s last known valuation is $51.0M (Sep 2025).
- It has raised $7.4M; the latest was Early Stage VC ($6.0M) in Sep 2025.
- Notable investors include Teamworthy Group, FCA Venture Partners.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Drug Hunter (Media and Information Services (B2B))
- ·The full record, as it builds
Funding rounds
No funding rounds for Drug Hunter (Media and Information Services (B2B)) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Drug Hunter (Media and Information Services (B2B))
Developer of a data-driven research platform designed to improve decision-making in early-stage drug discovery. The company's platform offers curated scientific content, real-time analysis of publications and patents, and an integrated search interface, enabling pharmaceutical R&D teams to uncover insights faster and tackle complex discovery challenges more effectively.
- Sector
- Business Products and Services (B2B)
- HQ
- Portland, OR, United States
- Founded
- 2021
- Employees
- 32
- Website
- drughunter.com/
- Ownership
- Privately Held (backing)
Drug Hunter (Media and Information Services (B2B)) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Drug Hunter (Media and Information Services (B2B)) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Drug Hunter (Media and Information Services (B2B)) in its N-PORT filings yet. We sweep new filings monthly.